Antibodies News and Research RSS Feed - Antibodies News and Research

Tampa General Hospital achieves Baby-Friendly hospital designation

Tampa General Hospital achieves Baby-Friendly hospital designation

Tampa General Hospital is the first hospital in Hillsborough County – and one of only three in the Tampa Bay area – to earn the Baby-Friendly hospital designation from Baby-Friendly USA, Inc. for its commitment to supporting breastfeeding mothers and their babies. [More]
Adaptive immune system plays active role in guiding development of mammary glands

Adaptive immune system plays active role in guiding development of mammary glands

In experiments with mouse tissue, UC San Francisco researchers have discovered that the adaptive immune system, generally associated with fighting bacterial and viral infections, plays an active role in guiding the normal development of mammary glands, the only organs--in female humans as well as mice--that develop predominately after birth, beginning at puberty. [More]
Continuous therapy improves multiple myeloma outcomes

Continuous therapy improves multiple myeloma outcomes

Patients with newly diagnosed multiple myeloma receive significant progression-free and overall survival benefits from continuous treatment compared with fixed-duration therapy, suggests a pooled analysis. [More]
Antiviral-based therapies have potential to protect humans from deadly Ebola virus

Antiviral-based therapies have potential to protect humans from deadly Ebola virus

For the first time, UK physicians have demonstrated that antiviral-based therapies have the potential to protect humans from the deadly Ebola virus. The report, published in The Lancet Infectious Diseases journal, describes a case-series of eight British health-care workers who were evacuated to the Royal Free Hospital in London, UK after possible accidental exposure to Ebola virus in Sierra Leone between January and March 2015. [More]
Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots. [More]
MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells. [More]
First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy. [More]
TSRI, Janssen collaborate to find universal flu vaccine

TSRI, Janssen collaborate to find universal flu vaccine

Scientists from The Scripps Research Institute and the Janssen Pharmaceutical Companies of Johnson & Johnson have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots. [More]
Mexican engineer designs new ring that can help diagnose sexually transmitted diseases

Mexican engineer designs new ring that can help diagnose sexually transmitted diseases

A ring with the ability to diagnose sexually transmitted diseases like syphilis, gonorrhea, chlamydia and trichomoniasis was designed by the Mexican Ernesto Rodríguez Leal. [More]
European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

Leaves of the European chestnut tree contain ingredients with the power to disarm dangerous staph bacteria without boosting its drug resistance, scientists have found. [More]
MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma. [More]
Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species, reported researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge." [More]
STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand. [More]
Experimental MERS-CoV vaccine shows promise in monkeys and camels

Experimental MERS-CoV vaccine shows promise in monkeys and camels

National Institutes of Health scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels. [More]
Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). [More]
NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax. [More]
MRI scanners can steer cell-based, tumour busting therapies to exact target sites in the body

MRI scanners can steer cell-based, tumour busting therapies to exact target sites in the body

Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body. [More]
Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain. [More]
Breastfeeding may lead to substantial reduction in common infections among Indigenous babies

Breastfeeding may lead to substantial reduction in common infections among Indigenous babies

Promoting breastfeeding could lead to a substantial reduction in common infections and even deaths that are more common in Indigenous infants than non-Indigenous infants, a new study suggests. [More]
Advertisement
Advertisement